Optimizing Antibiotic Therapy in Critically Ill Patients: The Role of Radiological Imaging and Pharmacokinetics in Infection Management

Aminah K. Alanazi[1], Maryam H. Aldossari[2], Fahad Alenizy[3], Zahra A. Asiri[4], Dima F. Almangour[5], Bader H. Alanazi[6], Ali A. Almalki[7], Maha S. Gassas[8], Rania A. Sharaf[9], Amer S. Alhumaidan[10], Ahmed A. Shareefi[11]

Health Affairs at the Ministry of National Guard

Abstract

Background: Managing infections in critically ill patients is challenging due to altered pharmacokinetics and complex disease processes. Integrating radiological imaging with pharmacokinetic monitoring may optimize antibiotic therapy.

Objective: This study assessed the impact of combining radiological imaging and therapeutic drug monitoring (TDM) on infection resolution and clinical outcomes in critically ill patients.

Methods: A prospective observational study was conducted with 120 critically ill patients at a tertiary hospital. Radiological imaging (chest X-rays, CT scans) and pharmacokinetic monitoring were used to guide antibiotic therapy. Clinical outcomes, including infection resolution, ICU stay, and mortality, were analyzed.

Results: Patients whose antibiotic doses were adjusted based on pharmacokinetic monitoring had significantly higher infection resolution rates (87% vs. 60%), shorter ICU stays (14.5 vs. 19.1 days), and lower mortality (11% vs. 27%). Radiological improvements were strongly correlated with achieving therapeutic drug levels ($p < 0.001$).

Conclusion: Combining radiological imaging with pharmacokinetic monitoring significantly improves infection resolution and clinical outcomes in critically ill patients, supporting a multidisciplinary approach to optimizing antibiotic therapy.

Keywords: critical care, pharmacokinetics, radiological imaging, antibiotic therapy, therapeutic drug monitoring, infection management

Introduction

Infections in critically ill patients present unique challenges in treatment due to the complexity of disease processes, altered pharmacokinetics, and the presence of multidrug-resistant organisms. Effective management of these infections, particularly in intensive care unit (ICU) settings, requires precise monitoring of both the infection and the pharmacological interventions used. One of the primary difficulties is ensuring that antibiotic therapy is optimized for efficacy while minimizing toxicity and preventing the development of resistance (Roberts et al., 2014).

Radiological imaging is a critical tool in diagnosing and monitoring infections in critically ill patients. Imaging techniques such as chest X-rays, computed tomography (CT) scans, and magnetic resonance imaging (MRI) provide detailed visualizations of infection progression, including pneumonia, intra-abdominal abscesses, and sepsis-related complications (Labaki et al., 2017). These imaging modalities allow clinicians to assess the severity of infection, detect complications, and evaluate the response to treatment over time.

In addition to imaging, understanding the pharmacokinetics of antibiotics in critically ill patients is essential to ensure proper dosing and therapeutic drug levels. Critical illness often results in altered pharmacokinetic parameters, including changes in drug absorption, distribution, metabolism, and excretion. For example, factors such as fluid resuscitation, organ dysfunction, and hypoalbuminemia can significantly affect drug clearance and volume of distribution (Roberts et al., 2014). Therapeutic drug monitoring (TDM) is therefore crucial in adjusting antibiotic doses to achieve optimal concentrations, improve treatment outcomes, and reduce the risk of toxicity (De Waele et al., 2014).

This study aims to assess how the integration of radiological imaging and pharmacokinetic monitoring can improve the management of infections in critically ill patients. By combining imaging to visualize the infection site with pharmacokinetic data to guide antibiotic dosing, we hypothesize that this multidisciplinary approach will lead to better infection control, reduced ICU stays, and improved patient outcomes.

Literature Review

Challenges of Infection Management in Critically Ill Patients

Infections in critically ill patients, particularly those in the ICU, are associated with high morbidity and mortality rates. The underlying disease processes, invasive procedures, and the frequent use of broad-spectrum antibiotics contribute to the complexity of managing these infections. Common infections in critically ill patients include ventilator-associated pneumonia, bloodstream infections, and intra-abdominal infections (Vincent et al., 2009). Effective treatment requires a precise balance of early diagnosis, optimal antibiotic selection, and careful monitoring of treatment response.

The critically ill patient's physiological state often results in altered pharmacokinetics and pharmacodynamics, which complicate antibiotic therapy. Factors such as fluid shifts, hypoalbuminemia, renal and hepatic dysfunction, and the use of extracorporeal support systems can significantly impact drug distribution, metabolism, and clearance (Roberts et al., 2014). These changes may lead to suboptimal drug levels, increasing the risk of treatment failure, drug toxicity, or the development of antibiotic resistance. Thus, optimizing antibiotic therapy in critically ill patients is a challenging yet essential aspect of infection management.

Role of Radiological Imaging in Infection Monitoring

Radiological imaging plays a key role in diagnosing, monitoring, and guiding the treatment of infections in critically ill patients. Imaging modalities such as chest X-rays, CT scans, and MRI are essential tools for visualizing infections, particularly when physical examination findings are limited due to the patient's critical condition. Chest X-rays are commonly used to monitor pneumonia, especially ventilator-associated pneumonia, providing insights into the extent and progression of lung involvement (Labaki et al., 2017). CT scans, particularly of the abdomen and pelvis, are instrumental in detecting intra-abdominal abscesses,

bowel perforations, and other complications that are difficult to diagnose through clinical examination alone (Emmi and Sganga, 2009).

Moreover, advanced imaging techniques such as positron emission tomography (PET) scans are increasingly used in the ICU setting to detect sepsis-related complications and monitor infection foci that may not be apparent through conventional methods (Kluge et al., 2012). Radiological imaging not only confirms the presence of an infection but also plays a critical role in assessing treatment efficacy by identifying whether infections are resolving or persisting, which can guide decisions on continuing, modifying, or discontinuing antibiotic therapy.

Pharmacokinetics of Antibiotics in Critical Care

Pharmacokinetic alterations in critically ill patients necessitate a tailored approach to antibiotic dosing. Critical illness frequently leads to changes in drug absorption, distribution, metabolism, and excretion, all of which can affect the pharmacokinetics of antibiotics. For example, patients in the ICU often experience increased volume of distribution due to fluid resuscitation, capillary leak syndrome, or hypoalbuminemia, which can reduce the concentration of antibiotics in tissues (Roberts et al., 2014). Additionally, organ dysfunction, particularly of the liver and kidneys, can lead to impaired drug clearance, further complicating dose optimization (Zaric et al., 2018).

Therapeutic drug monitoring (TDM) plays an essential role in ensuring that antibiotic concentrations remain within the therapeutic range. In particular, TDM is critical for antibiotics with a narrow therapeutic index, such as vancomycin and aminoglycosides, where suboptimal dosing can lead to either treatment failure or toxicity (De Waele et al., 2014). Studies have demonstrated that TDM-based dosing adjustments, particularly for β-lactam antibiotics, can improve patient outcomes by ensuring that drug concentrations are sufficient to eradicate pathogens while minimizing toxicity (Roberts et al., 2014).

Combining Imaging and Pharmacokinetics in Treatment Optimization

A multidisciplinary approach that integrates radiological imaging and pharmacokinetic monitoring is crucial for optimizing antibiotic therapy in critically ill patients. Imaging allows clinicians to assess infection progression and response to treatment in real time, while pharmacokinetic data ensure that antibiotics are dosed appropriately to achieve therapeutic levels. For instance, in the case of ventilator-associated pneumonia, serial chest X-rays can track improvements in lung consolidation, while TDM helps ensure that antibiotics such as vancomycin and meropenem are dosed to reach effective concentrations in lung tissues (Adrie et al., 2013).

In patients with complex intra-abdominal infections, CT imaging is often used to detect abscesses or other complications that may require drainage or surgical intervention. Simultaneously, TDM can guide the dosing of antibiotics like piperacillin-tazobactam, which requires careful adjustment in patients with fluctuating renal function (De Waele et al., 2014). By integrating both radiological findings and pharmacokinetic data, clinicians can make more informed decisions about the continuation or escalation of antibiotic therapy, reducing the risk of prolonged infection or drug-related adverse effects.

Antibiotic Resistance and the Importance of Dosing Precision

One of the most significant challenges in treating infections in critically ill patients is the emergence of antibiotic-resistant organisms. Inadequate antibiotic dosing, either due to underdosing or inappropriate duration of therapy, is a key driver of resistance in the ICU setting (Parkins et al., 2007). Ensuring that

antibiotics are dosed precisely to achieve therapeutic levels without promoting resistance is critical, particularly in patients with multidrug-resistant organisms.

Pharmacokinetic monitoring helps in avoiding subtherapeutic dosing, which can lead to the selection of resistant bacterial strains. Additionally, radiological imaging can detect early signs of treatment failure, such as persistent infection or abscess formation, which may indicate the need for alternative therapeutic strategies. Studies have shown that a combination of TDM and imaging can significantly improve outcomes in patients with resistant infections by optimizing both drug exposure and infection monitoring (Roberts et al., 2014).

Methodology

Study Design

This study employed a prospective observational design conducted over 12 months at a Tertiary Hospital. The aim was to assess the integration of radiological imaging and pharmacokinetic monitoring in optimizing antibiotic therapy for critically ill patients with infections. Ethical approval was obtained from the hospital's ethics committee.

Participants

A total of 120 critically ill patients diagnosed with infections, including ventilator-associated pneumonia, bloodstream infections, and intra-abdominal infections, were recruited from the hospital's intensive care unit (ICU). All participants were receiving antibiotic therapy during their ICU stay. Inclusion criteria were:

- Adult patients (≥18 years) admitted to the ICU with confirmed bacterial infections.
- Receiving intravenous antibiotic therapy (e.g., vancomycin, meropenem, piperacillin-tazobactam) with therapeutic drug monitoring (TDM).
- Radiological imaging performed as part of infection diagnosis or treatment monitoring (e.g., chest X-rays, CT scans).

Exclusion criteria included:

- Patients with terminal illness or palliative care plans.
- Those with known hypersensitivity to the antibiotics under study.
- Patients with severe renal or hepatic failure requiring dialysis, as this could alter pharmacokinetic profiles extensively.

Data Collection

1. Radiological Data

Radiological imaging was used to monitor infection progression and treatment response. All patients underwent baseline imaging (chest X-ray, CT, or MRI) within 24 hours of antibiotic therapy initiation, with follow-up imaging at 72 hours, 7 days, and as needed based on clinical judgment. Chest X-rays were used primarily for patients with suspected or confirmed pneumonia, while CT scans were utilized to assess intra-abdominal infections or abscesses. All imaging was interpreted by two independent radiologists blinded to the pharmacokinetic data and clinical outcomes.

2. Pharmacokinetics and Therapeutic Drug Monitoring (TDM)

Antibiotic levels were measured at predetermined intervals to assess pharmacokinetic parameters, including peak and trough levels, half-life, and clearance. Blood samples were collected 30 minutes after the end of

the infusion (for peak levels) and immediately before the next dose (for trough levels). The antibiotics monitored included:
- Vancomycin: Peak and trough levels were measured, with dosing adjusted to maintain a trough level of 15–20 mg/L.
- Meropenem: Pharmacokinetic data were used to adjust doses, aiming for free drug concentrations above the minimum inhibitory concentration (MIC) for at least 40% of the dosing interval.
- Piperacillin-tazobactam: TDM was used to optimize dosing, ensuring therapeutic levels were maintained, especially in patients with fluctuating renal function.

The pharmacokinetic data were analyzed by the hospital's clinical pharmacology team, who made dose adjustment recommendations to the treating physicians. Dose adjustments were based on the patient's pharmacokinetic profile, renal function, and clinical response.

3. Clinical Data
The following clinical data were collected:
- Infection Resolution: Defined as the resolution of infection symptoms (e.g., reduced fever, improvement in respiratory status, clearance of infection on imaging).
- Length of ICU stay: Measured from ICU admission to discharge or transfer.
- Hospital length of stay: Total duration from hospital admission to discharge.
- Mortality: In-hospital mortality was recorded for all patients.

Clinical data were collected by the attending ICU physicians and recorded in a standardized electronic health record system. Data on concomitant medications, renal and hepatic function, and fluid balance were also collected to account for variables affecting pharmacokinetics.

Data Analysis
1. Descriptive Statistics
Descriptive statistics were used to summarize patient demographics, infection type, antibiotic regimens, and baseline radiological and pharmacokinetic data. Continuous variables were expressed as means ±standard deviations, while categorical variables were reported as frequencies and percentages.

2. Comparative Analysis
Paired t-tests were used to assess changes in radiological findings from baseline to follow-up imaging, including the size of infection (e.g., lung infiltrates, abscesses). Changes in pharmacokinetic parameters (e.g., trough levels) were also analyzed over time. The effectiveness of antibiotic therapy was compared between patients with and without pharmacokinetic monitoring adjustments.

3. Correlation and Regression Analysis
Pearson correlation coefficients were calculated to assess the relationship between pharmacokinetic data (e.g., vancomycin trough levels) and radiological outcomes (e.g., improvement in lung infiltrates). Multiple regression analysis was used to identify independent predictors of infection resolution, with factors such as antibiotic levels, imaging changes, and patient comorbidities included in the model.

4. Clinical Outcomes
The primary outcome was infection resolution, based on clinical and radiological findings. Secondary outcomes included ICU and hospital length of stay, the need for escalation of antibiotic therapy, and in-

hospital mortality. Kaplan-Meier survival curves were generated to compare survival rates between patients whose antibiotic therapy was adjusted based on TDM versus those who did not receive TDM-based adjustments.

Ethical Considerations

All participants provided informed consent prior to inclusion in the study. Patient confidentiality was maintained by anonymizing all data, and the study was conducted in accordance with the ethical guidelines of Tertiary Hospitaland the Declaration of Helsinki.

Findings

This section presents the results of the study, including patient demographics, changes in radiological findings, pharmacokinetic data, and clinical outcomes. A total of 120 critically ill patients were included, all receiving antibiotic therapy with pharmacokinetic monitoring.

Patient Demographics

The study population included a diverse group of critically ill patients diagnosed with various infections. The mean age was 58.4 ±15.2 years, with a slightly higher proportion of males. The most common infection type was ventilator-associated pneumonia (VAP), followed by bloodstream infections and intra-abdominal infections.

Table 1: Patient Demographics and Baseline Characteristics

Characteristic	n (%)	Mean ±SD
Total participants	120	
Age (years)		58.4 ±15.2
Gender		
- Male	68 (57%)	
- Female	52 (43%)	
Infection type		
- Ventilator-associated pneumonia (VAP)	50 (42%)	
- Bloodstream infections	40 (33%)	
- Intra-abdominal infections	30 (25%)	
Baseline APACHE II score		21.5 ±5.7
Patients receiving vancomycin	70 (58%)	
Patients receiving meropenem	40 (33%)	
Patients receiving piperacillin-tazobactam	10 (8%)	

Radiological Outcomes

Significant improvements in infection resolution were observed in follow-up imaging. For patients with ventilator-associated pneumonia (VAP), chest X-rays showed a reduction in lung consolidation in 72% of

patients by day 7. CT scans for patients with intra-abdominal infections showed a 60% reduction in abscess size.

Table 2: Radiological Outcomes at Baseline and Follow-up

Radiological Finding	Baseline (n, %)	Follow-up at Day 7 (n, %)	p-value
Lung consolidation (VAP)	40 (80%)	10 (20%)	<0.001
Abscess (intra-abdominal infection)	18 (60%)	6 (20%)	0.002
Bacteremia resolution (bloodstream infection)	25 (62%)	35 (87%)	0.01

Pharmacokinetic Monitoring Results

Therapeutic drug monitoring (TDM) allowed for optimal dose adjustments in patients receiving vancomycin, meropenem, and piperacillin-tazobactam. In the vancomycin group, 75% of patients achieved the target trough levels (15–20 mg/L) after pharmacokinetic-guided dose adjustments. Patients receiving meropenem also benefited from dose adjustments, with 85% maintaining drug levels above the minimum inhibitory concentration (MIC) for their pathogens.

Table 3: Pharmacokinetic Data and Dose Adjustments

Antibiotic	Patients (n)	Achieved Target Levels (n, %)	Dose Adjustments (n, %)
Vancomycin (trough 15–20 mg/L)	70	52 (75%)	60 (86%)
Meropenem (above MIC for 40% of dosing interval)	40	34 (85%)	30 (75%)
Piperacillin-tazobactam	10	8 (80%)	7 (70%)

Clinical Outcomes

Patients whose antibiotic therapy was adjusted based on pharmacokinetic monitoring showed significantly better clinical outcomes compared to those who did not receive adjustments. Infection resolution, measured by clinical improvement and radiological findings, was higher in the pharmacokinetically monitored group. ICU and hospital length of stay were also shorter in the monitored group.

Table 4: Clinical Outcomes Based on Pharmacokinetic Monitoring

Outcome	Monitored (n = 90)	Not Monitored (n = 30)	p-value
Infection resolution	78 (87%)	18 (60%)	0.002

(%)			
ICU length of stay (days)	14.5 ±4.2	19.1 ±5.3	0.01
Hospital length of stay (days)	23.3 ±6.1	28.6 ±7.4	0.03
In-hospital mortality (%)	10 (11%)	8 (27%)	0.02

Correlation Analysis

There was a strong correlation between vancomycin trough levels and infection resolution in patients with bloodstream infections ($r = 0.65$, $p < 0.001$). Similarly, improvements in lung consolidation on chest X-ray were correlated with maintaining meropenem levels above the MIC ($r = 0.62$, $p < 0.001$).

Table 5: Correlation Between Pharmacokinetics and Radiological Outcomes

Variable	Radiological Outcome (r)	p-value
Vancomycin trough level	Bacteremia resolution (r = 0.65)	<0.001
Meropenem drug level	Lung consolidation improvement (r = 0.62)	<0.001

Summary of Findings

- Radiological imaging showed significant improvements in infection resolution, particularly in VAP and intra-abdominal infections, following antibiotic therapy.
- Pharmacokinetic monitoring led to successful dose adjustments, with the majority of patients achieving therapeutic antibiotic levels.
- Patients who received pharmacokinetically adjusted doses had better clinical outcomes, including higher infection resolution rates and shorter ICU stays.
- A strong correlation was observed between achieving therapeutic drug levels and radiological improvements in infection markers.

Discussion

This study assessed the impact of integrating radiological imaging with pharmacokinetic monitoring to optimize antibiotic therapy in critically ill patients with infections. The results demonstrate that combining these approaches significantly improves infection resolution, clinical outcomes, and hospital length of stay.

Key Findings

Radiological Improvements and Infection Resolution

The radiological data demonstrated significant improvements in infection markers, particularly for patients with ventilator-associated pneumonia (VAP) and intra-abdominal infections. By day 7, 72% of patients with VAP showed reduced lung consolidation on chest X-rays, and 60% of patients with intra-abdominal infections exhibited reduced abscess size on CT scans. These findings highlight the critical role of radiological imaging in tracking infection progression and response to antibiotic therapy. Imaging allows for real-time assessment of treatment efficacy, enabling clinicians to make timely adjustments to therapy based on visualized improvements or deterioration (Labaki et al., 2017).

Radiological findings served as a complementary tool to clinical assessments, providing objective evidence of infection resolution. This aligns with existing literature that emphasizes the importance of imaging in the management of infections in critically ill patients, particularly for detecting and monitoring complications that may not be apparent through clinical examination alone (Kluge et al., 2012).

Pharmacokinetic Monitoring and Dose Optimization

Therapeutic drug monitoring (TDM) played a key role in optimizing antibiotic therapy in this study, with 75% of patients on vancomycin achieving target trough levels and 85% of patients on meropenem maintaining drug concentrations above the minimum inhibitory concentration (MIC) for their pathogens. This highlights the value of pharmacokinetics in tailoring antibiotic doses to individual patient needs, particularly in the ICU setting where altered pharmacokinetics (e.g., due to fluid shifts, renal dysfunction, and organ failure) can complicate drug dosing (Roberts et al., 2011).

Patients whose antibiotic therapy was adjusted based on pharmacokinetic data had significantly better outcomes, including higher infection resolution rates (87% vs. 60%), shorter ICU stays (14.5 vs. 19.1 days), and reduced mortality (11% vs. 27%). These findings are consistent with previous studies that show pharmacokinetic-guided dose adjustments can improve drug efficacy while minimizing toxicity, particularly for antibiotics with narrow therapeutic windows such as vancomycin and meropenem (De Waele et al., 2014).

Improved Clinical Outcomes with Combined Approach

The integration of radiological imaging and pharmacokinetic monitoring was associated with markedly improved clinical outcomes. Patients in the pharmacokinetic monitoring group had shorter ICU and hospital stays and experienced fewer complications. The mortality rate was significantly lower in this group (11% vs. 27%), suggesting that achieving therapeutic drug levels through pharmacokinetic adjustments played a role in reducing treatment failures and improving survival.

The correlation between pharmacokinetics and radiological improvements further underscores the value of this combined approach. For example, vancomycin trough levels were strongly correlated with bacteremia resolution ($r = 0.65$, $p < 0.001$), and maintaining meropenem levels above the MIC was correlated with improvements in lung consolidation ($r = 0.62$, $p < 0.001$). These results support the notion that optimizing antibiotic exposure based on pharmacokinetic data enhances treatment efficacy, which is reflected in radiological markers of infection resolution.

Clinical Implications

The findings of this study have important clinical implications for the management of infections in critically ill patients. First, they underscore the necessity of a multidisciplinary approach that integrates both pharmacokinetics and imaging in the ICU. Radiological imaging provides critical insights into the progression of infections and helps to guide therapeutic decisions, while pharmacokinetics ensures that antibiotic dosing is optimized for each patient's unique physiological condition.

Second, the study demonstrates the value of routine therapeutic drug monitoring (TDM) in achieving target drug levels and improving patient outcomes. TDM should be considered a standard of care for antibiotics with significant variability in pharmacokinetics, particularly in ICU patients who may have fluctuating organ function and altered drug metabolism (Zaric et al., 2018).

Finally, the correlation between pharmacokinetic data and infection resolution, as seen in the strong association between therapeutic antibiotic levels and radiological improvements, suggests that clinical outcomes can be significantly enhanced by adjusting antibiotic therapy based on both drug concentration and imaging data. This approach can reduce treatment failures, prevent the development of drug resistance, and improve overall survival in critically ill patients.

Limitations

Several limitations of this study should be acknowledged. First, the study was conducted in a single tertiary hospital, which may limit the generalizability of the findings to other healthcare settings. Multicenter studies with larger patient populations are needed to validate these results and assess the broader applicability of this approach.

Second, while the study demonstrated significant benefits from pharmacokinetic monitoring, the study population was limited to patients receiving specific antibiotics (e.g., vancomycin, meropenem). Future studies should explore the role of pharmacokinetics for a wider range of antibiotics and in patients with other infection types.

Third, while radiological imaging provided valuable insights into infection progression, imaging techniques such as CT scans were not routinely used in all patients, particularly due to concerns about radiation exposure. More consistent use of advanced imaging modalities may provide even greater clarity on infection resolution.

Future Research

Future research should focus on expanding the study to include a broader range of antibiotics and infection types. In addition, longer follow-up periods are needed to assess the long-term impact of pharmacokinetic monitoring and radiological imaging on clinical outcomes, including rates of reinfection, readmission, and long-term survival.

Additionally, studies comparing different pharmacokinetic monitoring techniques and exploring more advanced imaging modalities (e.g., PET-CT) in the ICU setting may further enhance our understanding of how to optimize antibiotic therapy in critically ill patients.

Conclusion

This study demonstrates that integrating radiological imaging with pharmacokinetic monitoring significantly improves infection management in critically ill patients. The combination of real-time imaging to track infection progression and therapeutic drug monitoring to optimize antibiotic dosing leads to better infection resolution, shorter ICU stays, and reduced mortality. These findings highlight the importance of a multidisciplinary approach in the ICU, where individualized care based on both pharmacokinetics and imaging can optimize treatment outcomes and improve patient survival.

References:

1. Adrie, C., Schwebel, C., Garrouste-Orgeas, M., Vignoud, L., Planquette, B., Azoulay, E., ... & This article was written on behalf of the Outcomerea Study Group. (2013). Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. *Critical Care*, *17*, 1-12.

2. De Waele, J. J., Carrette, S., Carlier, M., Stove, V., Boelens, J., Claeys, G., ... &Verstraete, A. G. (2014). Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. *Intensive care medicine*, *40*, 380-387.
3. Emmi, V., &Sganga, G. (2009). Clinical diagnosis of intra-abdominal infections. *Journal of Chemotherapy*, *21*(sup1), 12-18.
4. Kluge, S., Braune, S., Nierhaus, A., Wichmann, D., Derlin, T., Mester, J., &Klutmann, S. (2012). Diagnostic value of positron emission tomography combined with computed tomography for evaluating patients with septic shock of unknown origin. *Journal of critical care*, *27*(3), 316-e1.
5. Labaki, W. W., Martinez, C. H., Martinez, F. J., Galbán, C. J., Ross, B. D., Washko, G. R., ... & Han, M. K. (2017). The role of chest computed tomography in the evaluation and management of the patient with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*, *196*(11), 1372-1379.
6. Parkins, M. D., Sabuda, D. M., Elsayed, S., &Laupland, K. B. (2007). Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. *Journal of antimicrobial chemotherapy*, *60*(3), 613-618.
7. Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., ... &Kuti, J. L. (2014). Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *The Lancet infectious diseases*, *14*(6), 498-509.
8. Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., ... &Soldatou, O. (2014). DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. *Clinical infectious diseases*, *58*(8), 1072-1083.
9. Vincent, J. L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C. D., ... & EPIC II Group of Investigators, X. (2009). International study of the prevalence and outcomes of infection in intensive care units. *Jama*, *302*(21), 2323-2329.
10. Zaric, R. Z., Milovanovic, J., Rosic, N., Milovanovic, D., Zecevic, D. R., Folic, M., & Jankovic, S. (2018). Pharmacokinetics of vancomycin in patients with different renal function levels. *Open Medicine*, *13*(1), 512-519.